Patents by Inventor James A. Matson

James A. Matson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial transformation method for the preparation of an epothilone
    Patent number: 7244594
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: July 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Microbial transformation method for the preparation of an epothilone
    Publication number: 20040176429
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Application
    Filed: March 23, 2004
    Publication date: September 9, 2004
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Microbial transformation method for the preparation of an epothilone
    Patent number: 6780620
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: August 24, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Antitumor antibiotics
    Patent number: 5643871
    Abstract: The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: July 1, 1997
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Thomas T. Dabrah, James A. Matson, Kin Sing Lam, Donald R. Gustavson, Grace A. Hesler, Ronald L. Berry
  • Rebeccamycin analogs by tryptophan analogs feeding
    Patent number: 5468849
    Abstract: Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: November 21, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Antitumor antibiotic BMY-41219
    Patent number: 5344823
    Abstract: A new antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 6, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Leonard A. McDonald, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Antitumor antibiotic BMY-41219
    Patent number: 5326754
    Abstract: An antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: July 5, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Kin S. Lam, Leonard A. McDonald, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Rebeccamycin
    Patent number: 5158938
    Abstract: Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: October 27, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, James A. Matson, Salvatore Forenza
  • BMY-40800 antitumor antibiotics
    Patent number: 5036010
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: April 26, 1990
    Date of Patent: July 30, 1991
    Assignee: Bristol-Myers Company
    Inventors: King S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • Antitumor antibiotic kedarcidin
    Patent number: 5001112
    Abstract: Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.
    Type: Grant
    Filed: March 17, 1989
    Date of Patent: March 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sandra J. Hofstead, James A. Matson, Kin S. Lam, Salvatore Forenza, James A. Bush, Koji Tomita
  • BMY-40800 antitumor antibiotics
    Patent number: 4994271
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: February 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Kin S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • Antibiotic, antitumor compounds and their use
    Patent number: 4743594
    Abstract: Actinomadura melliaura nov. sp. (ATCC 39691) produces four novel compounds which we have designated AT 2433 A.sub.1, AT 2433 A.sub.2, AT 2433 B.sub.1 and AT 2433 B.sub.2. The novel compounds or pharmaceutically acceptable salts thereof exhibit antibacterial and antitumor activity.
    Type: Grant
    Filed: September 17, 1984
    Date of Patent: May 10, 1988
    Assignee: Schering Corporation
    Inventors: Ann C. Horan, Jerzy Golik, James A. Matson, Mahesh G. Patel
  • Process for producing antitumor antibiotic compound
    Patent number: 4599310
    Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: September 25, 1985
    Date of Patent: July 8, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, James A. Bush
  • Albacarcins V and M
    Patent number: 4598145
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: July 1, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
  • Antitumor antibiotic compound
    Patent number: 4582639
    Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: April 15, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, James A. Bush
  • Process for preparing 4'-deschlororebeccamycin
    Patent number: 4567143
    Abstract: A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fermentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: March 18, 1985
    Date of Patent: January 28, 1986
    Assignee: Bristol-Myers Company
    Inventor: James A. Matson
  • 4'-Deschlororebeccamycin pharmaceutical composition and method of use
    Patent number: 4524145
    Abstract: A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fermentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: September 4, 1984
    Date of Patent: June 18, 1985
    Assignee: Bristol-Myers Company
    Inventor: James A. Matson
  • Antitumor agents albacarcins V and M
    Patent number: 4461831
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: August 16, 1982
    Date of Patent: July 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush